IL-WEBER
18.1.2022 15:07:08 CET | Business Wire | Press release
Weber Inc. (NYSE:WEBR), the global leader in outdoor cooking innovation, technology, and products, today unveiled the first three new products in its 2022 grilling portfolio. Designed to fuse the best in smart technology, high-quality materials, performance engineering, and craftsmanship, the 2022 GENESIS Smart Gas Grill, 2022 SMOKEFIRE Wood Fired Pellet Grill, STEALTH Edition, and all-new WEBER CRAFTED Outdoor Kitchen Collection take cooking outdoors to new levels of food discovery and exploration.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220118005538/en/
“Our product lineup for the upcoming barbecue season pushes the boundaries of the types of cooking that can be done outdoors, including bringing popular methods like flat top cooking and baking right to a WEBER grill,” said Jennifer Bonuso, Senior Vice President and General Manager, Global Product Management of Weber. “These new products are shaped by insights from grilling enthusiasts around the world, who crave to create more when they cook outside. We answered that desire by bringing together our best smart technology, new features, and a unique grillware collection.”
ABOUT THE NEW WEBER CRAFTED OUTDOOR KITCHEN COLLECTION
The WEBER CRAFTED Outdoor Kitchen Collection is a line of exclusive, high-quality, interchangeable grillware that enables a variety of different cooking methods. Outdoor cooks can use traditional grill grates or switch in a flat-top surface to open up a world of new foods at the grill, like eggs, pancakes, smashed burgers, and more. Exchange the grates for a baking stone for pizzas, crispy flatbreads, and cookies, or use rotisserie skewers for kabobs and roasted chicken. The Collection transforms the grill into a versatile, complete outdoor kitchen.
The WEBER CRAFTED line features six cooking pieces -- each providing a large cooking surface -- that facilitate steaming, baking, roasting, searing, or flat top cooking right at the grill. The complete grillware Collection consists of a Dual-Sided Sear Grate, Flat Top, Glazed Baking Stone, Roasting Basket, Wok & Steamer, and Rotisserie Skewer pieces. Additionally, it includes specially designed grates and an insert that allows the grillware pieces to be easily changed out on a WEBER gas, charcoal, or pellet grill.
Each WEBER CRAFTED item is sold separately.
ABOUT THE NEW WEBER GENESIS SMART GAS GRILL
The 2022 GENESIS Smart Gas Grill, Weber’s most advanced gas grill in 15 years, creates the ultimate culinary experience for grilling enthusiasts.
Built with high-quality materials, ingenuity, and the craftsmanship Weber is known for, the 2022 GENESIS grill is feature-packed to bring a complete outdoor kitchen experience to any outside space, including:
- WEBER CRAFTED Outdoor Kitchen Collection-ready with cooking grates specially designed to accommodate the WEBER CRAFTED grate insert and grillware pieces (sold separately) and unlock a wide range of cooking options at the grill.
- Integrated WEBER CONNECT smart grilling technology creates perfectly grilled food through real-time food temperature alerts, reminders, and flip and serve notifications at the grill or on the phone. With the WEBER CONNECT App, outdoor cooks can stay connected to their grill while taking care of guests, watching the game, or enjoying a drink.
- Proprietary PUREBLU high heat burners are designed to produce the most efficient, even flame for consistent, precise heat and reliable ignition.
- Extra-large SEAR ZONE allows outdoor cooks to sear multiple food items simultaneously.
- Extra-large Prep and Serve Table accommodates more trays and dishes than previous GENESIS models.
- NIGHTVISION motion-sensor, under-the-lid LED lights illuminate the entire grilling surface - from the side table to the grates. This patent-pending lighting system is ideal for early morning, dusk, and nighttime outdoor cooking.
- Expandable, Top Cooking Grate increases the overall available grilling space of the 2022 GENESIS grill, providing extra room to cook appetizers, sides, or main course dishes, all at the same time.
The 2022 GENESIS gas grill line includes several different three and four-burner models. In addition, models are available in porcelain-enamel or stainless steel finishes.
ABOUT THE NEW SMOKEFIRE WOOD PELLET GRILL, STEALTH EDITION
The 2022 SMOKEFIRE Wood Fired Pellet Grill, STEALTH Edition, brings a sleek, distinctive black-on-black aesthetic to Weber’s all-in-one SMOKEFIRE pellet grilling experience, which centers on exceptional wood fired flavor through both high heat searing and low and slow smoking,
The 2022 SMOKEFIRE Grill, STEALTH Edition, includes:
- All-black exterior styling.
- WEBER CRAFTED Outdoor Kitchen Collection - ready to open up the types of meals that can be made on a pellet grill, adding the ability to roast, steam, and even stir-fry.
- WEBER CONNECT smart grilling technology
- Built-in grill lighting illuminates the cooking grate for those extended evening or early morning cooks.
- A top cooking grate provides a large, second level of grilling capacity.
- Porcelain-enamel construction retains heat, even in cooler temperatures, and helps prevent rust and cracking.
The 2022 SMOKEFIRE Wood Fire Pellet Grill, STEALTH Edition series includes two models. Available models will vary by geographic region.
And to help inspire mealtime, Weber recently updated its popular WEBER CONNECT App with recipes, recipe collections, and additional cook programs that feature dishes and meal ideas that outdoor cooks can easily create with these new products. Weber owners can explore recipes for simple fare such as Balsamic Glazed Pork Chops with Peach Salsa and Grilled Carrots with Nutmeg Butter, to more sophisticated dishes such as Lemon-Ginger Tofu Steaks with Carrot and Cashew Salad or Chargrilled Oysters with Creole Remoulade Sauce and Grill Corn on the Cob with Basil Parmesan Butter.
The full 2022 GENESIS Gas Grill line and WEBER CRAFTED Outdoor Kitchen Collection will be available in the Americas and Europe leading up to the Spring barbecuing season from Weber websites and retail partners worldwide. In North America, consumers can purchase select models of the 2022 Genesis gas grill line and WEBER CRAFTED Collection online and in-store now. In addition, the 2022 SMOKEFIRE Wood Fired Pellet Grill, STEALTH Edition, will be available for purchase this Spring.
ABOUT WEBER INC.
Weber Inc. headquartered in Palatine, Ill., is the world’s leading barbecue brand. The Company’s founder George Stephen, Sr., established the outdoor cooking category when he invented the original kettle charcoal grill nearly 70 years ago. Weber offers a comprehensive, innovative product portfolio, including charcoal, gas, pellet and electric grills, smokers, and accessories designed to help outdoor cooking enthusiasts discover what’s possible. In 2021, the Company acquired June Life Inc., a smart appliance and technology company, to accelerate the development of its Weber Connect technology and digital products. In addition, Weber recently launched 1952 Ventures , a subsidiary designed to accelerate new growth platforms and brand extensions for the Company in the areas of product, technologies, and partnerships. Weber offers its barbecue grills and accessories, services, and experiences to a passionate community of millions across 78 countries.
WEBER®, GENESIS®, SMOKEFIRE®, and WEBER CONNECT® are U.S. registered trademarks; STEALTH; NIGHTVISION, PUREBLUE, and SEAR ZONE are trademarks; all owned by Weber-Stephen Products LLC.
FUTURE STATEMENTS
This press release contains various “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, which represent Weber’s expectations or beliefs concerning future events. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue,” the negative of these terms and other comparable terminology. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements, including those factors listed in the Company's filings with the Securities and Exchange Commission, including the most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K.
Our future results could be affected by a variety of other factors, including uncertainty of the magnitude, duration, geographic reach, impact on the global economy and current and potential travel restrictions of the COVID-19 outbreak, the current, and uncertain future, impact of the COVID-19 outbreak on our business, growth, reputation, prospects, financial condition, operating results (including components of our financial results), and cash flows and liquidity, risks relating to any unforeseen changes to or effects on liabilities, future capital expenditures, revenues, expenses, earnings, synergies, indebtedness, financial condition, losses and future prospects, the ability to realize the anticipated benefits and synergies from business acquisitions in the amounts and at the times expected, the impact of competitive conditions, the effectiveness of pricing, advertising, and promotional programs; the success of innovation, renovation and new product introductions; the recoverability of the carrying value of goodwill and other intangibles, the success of productivity improvements and business transitions, commodity and energy prices, transportation costs, labor costs, disruptions or inefficiencies in supply chain, the availability of and interest rates on short-term and long-term financing, the levels of spending on systems initiatives, properties, business opportunities, integration of acquired businesses, and other general and administrative costs, changes in consumer behavior and preferences, the effect of U.S. and foreign economic conditions on items such as interest rates, statutory tax rates, currency conversion and availability, legal and regulatory factors including the impact of any product recalls; and business disruption or other losses from war, pandemic, terrorist acts or political unrest.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220118005538/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
